VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
* Login to view program details and full enterprise executive list.
DATE
JUL 2020
TABLES
168
PAGES
222
EDITION
17
PRICE
USD $5450
The World of Intravenous Immunoglobulin (IVIg) is Changing Fast!
It's Time to Identify Upcoming Revenue Pockets & Growth Areas.
INSIDER ACCESS PRIVILEGES
KEY DIFFERENTIATORS
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Immunoglobulins to See Steady Growth |
| Recent Market Activity |
| Intravenous Immunoglobulin - A Proliferating Biologic |
| Application Areas - A Brief Review |
| Market Outlook |
| Growth Drivers and Market Challenges |
| Competitive Scenario |
| Grifols Continues to Consolidate Market Position |
| CSL Sees Robust Growth in Immunoglobulin Franchise |
| Shire Continues to Invest Big in Immunoglobulins |
| Bivigam Changes Hands Consequent to Unexpected Turn of Events |
| Global Competitor Market Shares |
| Intravenous Immunoglobulin (IVIg) Competitor Market Share Scenario Worldwide (in %): 2018 & 2025 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Bharat Serums and Vaccines Limited (India) |
| Biotest AG (Germany) |
| China Biologic Products, Inc. (China) |
| Guizhou Taibang Biological Products Co., Ltd (China) |
| CSL Limited (Australia) |
| Grifols, S.A. (Spain) |
| Hualan Biological Engineering Inc. (China) |
| Kedrion S.p.A. (Italy) |
| LFB Group (France) |
| Octapharma AG (Switzerland) |
| Shanghai RAAS Blood Products Co., Ltd. (China) |
| Shire plc (Ireland) |
| Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China) |
| 3. MARKET TRENDS & DRIVERS |
| Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth of Immunoglobulins |
| Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market |
| IVIg - The Mainstay of PI Therapy |
| Subcutaneous IG Formulations Gain Therapeutic Foothold |
| Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead |
| Unsuccessful Clinical Trials for Alzheimer's - A major Setback for IVIg Market |
| Synthetic Replacements to IVIg Therapy |
| IVIg Therapy - Home-based vs. Outpatient Settings |
| Per Capita Consumption Rate Varies Across Countries |
| Favorable Reimbursement and High Usage make US the Largest Consumer |
| Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID |
| Aging Global Population: Major Opportunity Indicator |
| Improving Healthcare Expenditure to Foster Growth |
| IV. COMPETITION |
| Total Companies Profiled : 24 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com